Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimoclomol Open-Label Extension in IBM
NCT04049097Phase 3Terminated
- Sponsor
- Zevra Therapeutics
- Start
- May 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of arimoclomol in inclusion body myositis (IBM), sponsored by Zevra Therapeutics. Primary endpoint: Inclusion Body Myositis Functional Rating Scale Total Score at 28 weeks. Started May 2019; status: terminated.
02
Drugs
arimoclomol
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT04049097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049097.